Treatment strategies for hepatocellular carcinoma in Japan

Hepatology Research

Volumn 43, Issue 1, 2013, Pages 44-50

  Yamashita, Tatsuya ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Treatment algorithm; Treatment strategies

Indexed keywords

ANTINEOPLASTIC AGENT; BRANCHED CHAIN AMINO ACID; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GELATIN SPONGE; GELFOAM; GLYCYRRHIZIC ACID; HUMAN SERUM ALBUMIN TC 99M; INDOCYANINE GREEN; INTERFERON; MIRIPLATIN; PENTETATE TECHNETIUM TC 99M; SORAFENIB; URSODEOXYCHOLIC ACID;

ALGORITHM; ANOREXIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONSENSUS DEVELOPMENT; DIARRHEA; EARLY DIAGNOSIS; FATIGUE; HAND FOOT SYNDROME; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATIC ARTERY; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; JAPAN; LAPAROSCOPIC SURGERY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; PEPTIC ULCER; PHLEBOTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTON THERAPY; RADIOFREQUENCY ABLATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC BODY RADIATION THERAPY; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULITIS; VOMITING;

EID: 84872669875     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01029.x     Document Type: Review

References (55)

1. Kudo M, Izumi N, Kokudo N etal. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-64.
2. Clinical Practice Guidelines for hepatocellular carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res 2010; 40 (Suppl 1): 2-144.
3. Kishi Y, Saiura A, Yamamoto J etal. Significance of anatomic resection for early and advanced hepatocellular carcinoma. Langenbecks Arch Surg 2012; 397: 85-92.
4. Wakai T, Shirai Y, Sakata J etal. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol 2007; 14: 1356-65.
5. Makuuchi M, Hasegawa H, Yamazaki S. Indication for hepatectomy in patients with hepatocellular carcinoma and cirrhosis (in Japanese). Shindan to Chiryo 1986; 1986: 1225-30.
6. Kaibori M, Ha-Kawa SK, Maehara M etal. Usefulness of Tc-99m-GSA scintigraphy for liver surgery. Ann Nucl Med 2011; 25: 593-602.
7. Nanashima A, Abo T, Tobinaga S etal. Prediction of indocyanine green retention rate at 15 minutes by correlated liver function parameters before hepatectomy. J Surg Res 2011; 169: e119-25.
8. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-85.
9. Ikai I, Kudo M, Arii S etal. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010; 40: 1043-59.
10. Ueno S, Sakoda M, Kurahara H etal. Preoperative segmentation of the liver, based on 3D CT images, facilitates laparoscopic anatomic hepatic resection for small nodular hepatocellular carcinoma in patients with cirrhosis. Hepatogastroenterology 2010; 57: 807-12.
11. Suzuki H, Shimura T, Suehiro T etal. Laparoscopic partial liver resection for hepatocellular carcinoma in liver cirrhosis. Hepatogastroenterology 2008; 55: 2228-32.
12. Kaneko H, Takagi S, Otsuka Y etal. Laparoscopic liver resection of hepatocellular carcinoma. Am J Surg 2005; 189: 190-4.
13. Kitisin K, Packiam V, Bartlett DL, Tsung A. A current update on the evolution of robotic liver surgery. Minerva Chir 2011; 66: 281-93.
14. Ku Y, Iwasaki T, Tominaga M etal. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg 2004; 239: 53-60.
15. Liver transplantation in Japan - registry by the Japanese Liver Transplantation Society - (in Japanese) - registry by the Japanese Liver Transplantation Society- Ishoku 2010; 45: 621-32.
16. Sakaguchi T, Suzuki S, Morita Y etal. Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria. Surg Today 2010; 40: 638-45.
17. Hasegawa K, Imamura H, Ijichi M etal. Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462). J Gastrointest Surg 2008; 12: 858-66.
18. Matsuno N, Iwamoto H, Nakamura Y etal. ABO-incompatible adult living donor liver transplantation for hepatocellular carcinoma. Transplant Proc 2008; 40: 2497-500.
19. Shiina S, Teratani T, Obi S etal. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-30.
20. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004; 127: 1714-23.
21. Lencioni RA, Allgaier HP, Cioni D etal. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-40.
22. Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009; 9: 31.
23. Asahina Y, Nakanishi H, Izumi N. Laparoscopic radiofrequency ablation for hepatocellular carcinoma. Dig Endosc 2009; 21: 67-72.
24. Inoue T, Minami Y, Chung H etal. Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases. Oncology 2010; 78 (Suppl 1): 94-101.
25. Uehara T, Hirooka M, Ishida K etal. Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites. J Gastroenterol 2007; 42: 306-11.
26. Rhim H, Lim HK. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites. Abdom Imaging 2009; 34: 371-80.
27. Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: initial experience. AJR Am J Roentgenol 2008; 190: 91-8.
28. Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol 2009; 19: 2630-40.
29. Ogawa T, Kawamoto H, Kobayashi Y etal. Prevention of biliary complication in radiofrequency ablation for hepatocellular carcinoma-Cooling effect by endoscopic nasobiliary drainage tube. Eur J Radiol 2010; 73: 385-90.
30. Masuzaki R, Shiina S, Tateishi R etal. Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26: 759-64.
31. Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y, Terae S, Shirato H. Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. Jpn J Radiol 2009; 27: 185-93.
32. Nakai M, Sato M, Sahara S etal. Radiofrequency ablation assisted by real-time virtual sonography and CT for hepatocellular carcinoma undetectable by conventional sonography. Cardiovasc Intervent Radiol 2009; 32: 62-9.
33. Matsui O, Kadoya M, Yoshikawa J etal. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: 79-83.
34. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 1994; 33 (Suppl): S84-8.
35. Takayasu K, Arii S, Kudo M etal. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56: 886-92.
36. Okabe K, Beppu T, Haraoka K etal. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma. Anticancer Res 2011; 31: 2983-8.
37. Okusaka T, Kasugai H, Ishii H etal. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs 2011; doi. 10.1007/s10637-011-9776-4.
38. Takayasu K. Chemoembolization for unresectable hepatocellular carcinoma in Japan. Oncology 2010; 78 (Suppl 1): 135-41.
39. Nagano H, Miyamoto A, Wada H etal. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 2007; 110: 2493-501.
40. Nagano H, Wada H, Kobayashi S etal. Long-term outcome of combined interferon-alpha and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011; 80: 63-9.
41. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-65.
42. Kaneko S, Furuse J, Kudo M etal. Guideline on th euse if new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res 2012 (in press).
43. Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: a multicenter, randomized, phase II study. Hepatol Res 2012; 42: 150-65.
44. Obi S, Yoshida H, Toune R etal. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.
45. Yamashita T, Arai K, Sunagozaka H etal. Randomized, Phase II Study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 281-90.
46. Ueshima K, Kudo M, Takita M etal. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010; 78 (Suppl 1): 148-53.
47. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-95.
48. Tanioka H, Tsuji A, Morita S etal. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23: 1891-7.
49. Chung YH, Song IH, Song BC etal. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-91.
50. McIntosh A, Hagspiel KD, Al-Osaimi AM etal. Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. Cancer 2009; 115: 5117-25.
51. Komatsu S, Fukumoto T, Demizu Y etal. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011; 117: 4890-904.
52. Sugahara S, Oshiro Y, Nakayama H etal. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 76: 460-6.
53. Yoshida H, Shiratori Y, Kudo M etal. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011; 54: 532-40.
54. Berrino F, De Angelis R, Sant M etal. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-83.
55. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.